Tubocapsenolide A Overcomes Oxaliplatin Resistance in Colorectal Cancer by Targeting the PLK1-CEP55-ESCRT Axis to Suppress Nuclear Budding and Mitochondrial-derived Vesicles Extrusion
Oxaliplatin (L-OHP) is a first-line chemotherapeutic agent for both advanced colorectal cancer (CRC) and postoperative adjuvant therapy. However, the development of acquired L-OHP resistance remains a major clinical obstacle. Here, we identify Tubocapsenolide A (TA), a natural withanolide isolated from Tubocapsicum anomalum , as a potent antitumor agent that not only suppresses CRC growth but also effectively reverses acquired L-OHP resistance. Using a PROTAC-based target deconvolution strategy combined with biophysical validation, we demonstrate that PLK1 is the direct functional target of TA. PLK1 is aberrantly overexpressed in L-OHP-resistant CRC and negatively correlates with patient sensitivity to L-OHP. Mechanistically, overexpressed PLK1 hyperphosphorylates the adaptor protein CEP55 to recruit the ESCRT machinery, driving a previously unappreciated PLK1-CEP55-ESCRT-dependent vesicular extrusion process. This enables resistant cells to rapidly clear L-OHP-induced damage through γ-H2A.X⁺ nuclear budding and TOM20⁻/PDH⁺ mitochondrial-derived vesicles, thereby preserving organelle integrity and promoting cell survival. By directly binding and inhibiting PLK1, TA disrupts the CEP55-ESCRT-dependent membrane scission machinery, leading to intracellular accumulation of damaged components. Consequently, it triggers severe nucleolar stress and mitochondrial dysfunction, ultimately inducing death in L‑OHP‑resistant cells. Collectively, our findings uncover a novel PLK1-CEP55-ESCRT-driven vesicular extrusion mechanism underlying L-OHP resistance and establish targeting this axis as a promising therapeutic strategy for chemorefractory CRC. TA represents a valuable lead compound for the development of new treatments against L-OHP-resistant CRC.